Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tammy Robinson

Nurse Practitioner Flowood, MS Nurse Practitioner

NPI 1912571977 CMS profile 10582679

2610 Courthouse Cir, Flowood, MS 39232

Open in the dashboard

General payments

$4,763

177 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tammy Robinson of Flowood, MS is reported in the CMS Open Payments database as having received $4,763 across 177 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,047 32
2024 General $774 7
2023 General $53 3
2022 General $1,487 75
2021 General $1,402 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tammy Robinson
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Tammy Robinson were reported at $1,047. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Tammy Robinson Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,402 $135 $40–$426 $132
2022 $1,487 $152 $48–$470 $149
2023 $53 $166 $54–$529 $160
2024 $774 $173 $55–$556 $164
2025 $1,047 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $755 26 payments
  2. Boston Scientific Corporation $632 5 payments
  3. Novo Nordisk Inc $554 17 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $299 15 payments
  5. Amgen Inc. $292 7 payments
  6. Lilly USA, LLC $275 21 payments
  7. Medtronic, Inc. $263 7 payments
  8. Sanofi-Aventis U.S. LLC $254 10 payments
  9. AstraZeneca Pharmaceuticals LP $235 10 payments
  10. Spinal Simplicity, LLC $192 2 payments
  11. Other $1,013 57 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,414 175 payments
  2. Travel and Lodging $337 1 payment
  3. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. Intracept $632 5 payments
  2. RYBELSUS $340 15 payments
  3. Kerendia $299 15 payments
  4. ETERNA $261 8 payments
  5. SOLIQUA 100/33 $254 10 payments
  6. FARXIGA $235 10 payments
  7. INTELLIS ADAPTIVESTIM $223 5 payments
  8. Ozempic $221 14 payments
  9. HA MINUTEMAN G3-R $192 2 payments
  10. PROCLAIM $169 10 payments
  11. Other $2,296 112 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

1,093

Median for Nurse Practitioner: 389

Drug cost

$29,275

Median for Nurse Practitioner: $21,885

Branded share of claims

58.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 15 $12,084
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 278 $7,314
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 321 $5,406
Gabapentin Generic 122 $1,374
Pregabalin Generic 69 $633
Tizanidine Hcl Generic 71 $469
Oxycodone Hcl Generic 20 $365
Cyclobenzaprine Hcl Generic 43 $308
Acetaminophen-Codeine Acetaminophen With Codeine Brand 24 $288
Tramadol Hcl Generic 48 $281

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$20,996

Medicare's payments for the services billed

Medicare patients

67

Average age 67

Services billed

385

50 women, 17 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 45%
Depression 30%
COPD 28%
Ischemic heart disease 19%
Heart failure 18%
Chronic kidney disease 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

177 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record